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Abstract
Left ventricular mass (LVM) and cardiac gene expression are complex traits regulated by factors
both intrinsic and extrinsic to the heart. To dissect the major determinants of LVM, we combined
expression quantitative trait locus1 and quantitative trait transcript2 (QTT) analyses of the cardiac
transcriptome in the rat. Using these methods and in vitro functional assays, we identified
osteoglycin (Ogn) as a major candidate regulator of rat LVM, with increased Ogn protein
expression associated with elevated LVM. We also applied genome-wide QTT analysis to the
human heart and observed that, out of ~22,000 transcripts, OGN transcript abundance had the
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highest correlation with LVM. We further confirmed a role for Ogn in the in vivo regulation of
LVM in Ogn knockout mice. Taken together, these data implicate Ogn as a key regulator of LVM
in rats, mice and humans, and suggest that Ogn modifies the hypertrophic response to extrinsic
factors such as hypertension and aortic stenosis.
Elevated indexed LVM is a major cause of morbidity and mortality and is regulated, in part,
by hemodynamic indices3. However, only a small proportion of LVM variation is
determined by hemodynamic effects4, and it has been proposed that genetic influences may
also be important5,6. Many studies have shown that gene expression is heritable and that the
genetic control of transcription affects physiological traits and disease phenotypes1,7. We
have shown that gene transcription is highly heritable in the rat heart8, which led us to
hypothesize that the genetic control of cardiac gene expression may be important in
regulating LVM. Here, we used an integrated approach combining correlation of expression
quantitative trait loci (eQTL)1 and genome-wide expression profiles with physiological
traits, previously designated as quantitative trait transcript (QTT) analysis2, to identify
genetic determinants of LVM.
We examined regulation of LVM using the BXH/HXB panel of rat recombinant inbred (RI)
strains, derived from a cross of the Brown Norway (BN) rat and the spontaneously
hypertensive rat (SHR)1. We generated blood pressure telemetry data across the RI strains
to assess the influence of averaged blood pressure on LVM (Supplementary Fig. 1 online).
Our data showed that LVM correlated poorly with physiological variation in blood pressure
(Supplementary Fig. 1b). Previous studies have shown an effect of extreme pressure
overload on cardiac gene expression9; however, apart from a small subset of genes
(Supplementary Table 1 online), we observed limited correlation with systolic blood
pressure (SBP, median r = 0.14, 25th–75th percentiles 0.07–0.23) or diastolic blood pressure
(DBP, median r = 0.13, 25th–75th percentiles 0.06–0.22). These findings are consistent with
a recent study that showed limited effects of blood pressure on cardiac gene expression in
three hypertensive rat strains, including the SHR10.
We then carried out eQTL analysis in the rat heart and detected 1,444 cis and 2,300 trans
eQTLs at a genome-wide corrected P value (PGW) of 0.05 (Supplementary Fig. 2a,b
online), with a predominance of cis eQTLs at more stringent P values (Supplementary Fig.
2c). Robustly mapped cis-regulated transcripts (false discovery rate (FDR) <5%, relative
change >1.5) in the heart that colocalize with previously mapped cardiac mass or LVM
QTLs represent candidate genes for these traits in the rat (Supplementary Tables 2 and 3
online). Two of these candidate genes, α1β-adrenergic receptor (Adra1b) and thioredoxin 2
(Txn2), are major determinants of cardiac hypertrophy in the mouse11,12.
We next performed genome-wide QTT analysis for all eQTLs against LVM, SBP and DBP
(Supplementary Table 4 online) to identify cis eQTLs that correlated with LVM but not
with blood pressure as primary candidate genes for the regulation of LVM. We observed the
most significant QTT for a group of nine cis-regulated transcripts that were highly correlated
with LVM and were encoded on chromosome 17p14 (Fig. 1a). Neither SBP nor DBP
showed significant association with LVM by QTT analysis at this locus (Fig. 1b,c). This
genomic region contains a QTL for LVM in the BXH/HXB RI strains5 that we refined using
additional microsatellite markers. A peak lod score of 3.98 was observed at the genetic
marker Drd1a. Within the 2-lod support interval for this QTL (~7 cM), 113 transcripts (out
of 151) reached nominal significance (P < 0.05) of cis linkage (Fig. 2a,b), and 23 transcripts
remained significant after Bonferroni correction for multiple testing. We prioritized cis
eQTLs that correlated with LVM as candidate genes on the basis of the significance of their
cis linkage and the extent of their differential expression, as previously described13. This
identified two genes: the extracellular matrix (ECM) protein osteoglycin (Ogn; P = 1.9 ×
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10−8) and an iron-sulfur cluster assembly-1 (Saccharomyces cerevisiae) homolog (Isca1;
also known as HesB-like domain–containing 2 (Hbld2); P = 5.9 × 10−7) (Fig. 2b). We then
fine-mapped the LVM QTL using SNPs, which excluded Hbld2 as a positional candidate
(Supplementary Table 5 online). These analyses prioritized Ogn as the only cis-regulated
transcript that was both highly differentially regulated and correlated with LVM, but they do
not exclude influences from other genes within the refined QTL interval. Sequence analysis
of Ogn revealed several SNPs and a 47-bp indel in the 3′ UTR of the gene (Fig. 2c).
Subsequently, we used primary cultures of neonatal cardiac myocytes to examine the
regulation of Ogn in response to hypertrophic stimulation by phenylephrine; this is an
established and blood pressure–independent in vitro model of cardiac myocyte
hypertrophy14. During the course of the hypertrophic response, Ogn transcript levels were
significantly downregulated (Fig. 2d). As expected, natriuretic peptide precursor A (Nppa), a
biomarker of cardiac hypertrophy, was upregulated in the model14 (Supplementary Fig. 3a
online). Adra1b and Txn2 (Supplementary Fig. 3b,c), established determinants of LVM in
the mouse11,12 and candidate genes in the rat (Supplementary Table 2), showed dynamic
regulation similar to that observed for Ogn. These eQTL, QTT and in vitro results, taken
together with recent finding that ECM proteins are critical determinants of cardiac
hypertrophy15,16, prioritize Ogn as a strong positional and biological candidate for LVM in
the rat.
To translate our findings to humans, we generated genome-wide expression profiles of the
human heart using biopsies collected from 20 individuals with aortic stenosis and elevated
LVM and from seven control subjects. From this cohort, we selected subjects at the
extremes of the distribution of LVM (see Methods) to identify genes that show strong
differential regulation between individuals with high and low LVM. Differentially regulated
genes (FDR ≤ 5%, relative change >1.5) that correlated most highly with LVM across the
study population are reported in Table 1. Notably, out of the 22,284 transcripts considered,
OGN, the human ortholog of rat Ogn, correlated most strongly with LVM, and this
correlation remained significant after controlling for the presence or absence of aortic
stenosis (r = 0.45, P = 0.02). NPPA and natriuretic peptide precursor B (NPPB), biomarkers
of cardiac hypertrophy, were upregulated in individuals with aortic stenosis (aortic stenosis
versus controls; relative change = 2.6, P = 0.006 and relative change = 9.5, P = 0.01,
respectively); however, unlike OGN, they did not significantly correlate with LVM when
the test was made conditional on aortic stenosis status. We then analyzed two more
published microarray datasets and independently replicated the association of OGN with
increased LVM and markers of hypertrophy in these cohorts (Supplementary Table 6
online).
In our cohort of all subjects considered for the biopsy studies, we observed a weak
correlation of LVM with peak velocity across the aortic valve (Vmax; Fig. 3a) and aortic
valve area index (AVAI; Fig. 3b), established clinical measures of aortic stenosis severity17.
However, as calculation of LVM by echocardiography relies on assumptions of left
ventricular geometry, we studied an independent cohort of subjects with aortic stenosis in
which LVM, Vmax and AVAI were assessed by cardiac MRI. This confirmed limited effects
of pressure indices on variation in LVM (Fig. 3c,d). Our data suggest that the severity of
aortic valve narrowing, the major extrinsic stimulus for LVM in patients with aortic stenosis,
determines only a limited amount of LVM variation.
On review of the association of Ogn expression with LVM, we observed an apparent
inconsistency in the direction of the correlation between species (r = −0.46, rat; r = 0.62,
human). However, differential expression, as determined by microarrays, can reflect
sequence variation or alternative splicing in the 3′ UTR18. Further analysis revealed that, of
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four microarray probe sets for rat Ogn, two mapped as cis eQTLs and correlated with LVM
variation, whereas two did not (Supplementary Fig. 4 online), suggestive of alternative
splicing in the 3′ UTR, which was confirmed by RT-PCR (Fig. 4a). This alternative splicing
resulted in two isoforms of the 3′ UTR: a short isoform (~106 bp) that was more abundant
in the BN strain and a long isoform (~1,560 bp) that was more abundant in the SHR strain
(Fig. 4b). The allelic effect of the 47-bp sequence polymorphism (Fig. 2c) on the abundance
of the 3′ UTR isoforms was confirmed across the RI strains (P < 10−11 for both isoforms;
Fig. 4c). By luciferase assay, the short isoform was more efficient for protein production
than the long isoform (Fig. 4d), and there was three times the expression of Ogn protein in
BN heart as in SHR heart (Fig. 4e,f). To determine the cell types expressing Ogn in the
heart, we examined primary cultures of neonatal cardiac myocytes and cardiac fibroblasts,
which revealed equivalent Ogn protein expression in these cell types, with greater secretion
of Ogn by fibroblasts (Supplementary Fig. 5 online). We confirmed expression of Ogn in
isolated adult rat cardiac myocytes by confocal microscopy, which revealed association of
Ogn with the sarcomere (Fig. 4g).
Our data showed that the BN genotype at chromosome 17p14, associated with the 47-bp
insertion, accounted for a considerable amount (47%) of LVM variation in the RI strains;
factors explaining the remaining phenotypic variation are unknown. As the Ogn sequence
variant is associated with high LVM, independently of blood pressure, and correlates with
increased Ogn protein expression (Fig. 4e,f), we suggest that the 47-bp insertion, present in
the BN and other strains (Supplementary Figs. 4, 6 and 7 online), promotes splicing of the
Ogn 3′ UTR, and that the greater abundance of the short isoform in the BN results in higher
amounts of Ogn protein. We further determined the Ogn 3′ UTR indel across 30 rat strains,
selected for protein studies four strains with the insertion and five strains without and
confirmed the association of the insertion with increased Ogn (P = 0.008) (Supplementary
Fig. 7).
The association of Ogn transcript abundance with LVM in rats and humans led us to
hypothesize that Ogn protein expression might be central to hypertrophic response
irrespective of the stimulus, which could be physiological or pathophysiological. To
examine this, we studied an independent cohort of individuals with concentric hypertrophy
secondary to aortic stenosis or hypertensive heart disease or eccentric hypertrophy
secondary to ischemic heart failure (Supplementary Table 7 online). We observed that high
amounts of OGN protein were associated with elevated LVM (Spearman's correlation = 0.7,
P = 0.019) whereas neither SBP (Spearman's correlation =0.1, P = 0.4) nor DBP
(Spearman's correlation = 0.02, P = 0.5) correlated with OGN protein (Supplementary
Table 7 and Supplementary Fig. 8 online).
To validate functionally the role of Ogn in the in vivo regulation of LVM, we studied Ogn
knockout (Ogn−/−) mice19. Although we observed no difference in LVM in Ogn−/− mice as
compared to controls at baseline (Fig. 5a), it is established that permissive physiological
perturbations are frequently required to reveal cardiovascular phenotypes in knockout
mice9,20. Therefore, we used subcutaneous angiotensin II infusion as a pro-hypertrophic
stimulus and observed that Ogn+/− and Ogn−/− mice showed a significant attenuation (P =
0.002 and P = 0.02, respectively) in LVM response as compared to Ogn+/+ controls. We
then determined the expression of Nppa, Nppb and α-skeletal smooth muscle actin (Acta1, a
structural cellular marker of hypertrophy). This showed a significant reduction in Acta1 (P =
0.02) in the Ogn−/− mice after angiotensin II infusion (Supplementary Table 8 online), in
keeping with the effects of other ECM proteins on the hypertrophic response21. Although
there was no difference in SBP or DBP between the Ogn+/+ controls and either Ogn+/− or
Ogn−/− mice at baseline, we observed a significant increase in DBP in the Ogn−/− mice
during angiotensin II infusion (Fig. 5b). The effect of Ogn on LVM remained apparent
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despite the Ogn−/− mice having a higher blood pressure, which may be due to noncardiac
effects of Ogn deletion.
In summary, our data implicate Ogn as an important regulator of LVM in rats, mice and
humans. Our data show that sequence variation in the Ogn 3′ UTR in the rat, which has
multiple forms in other species22, is associated with increased Ogn protein expression and
elevated LVM. The ENCyclopedia Of Dna Elements (ENCODE) pilot project highlighted
an enrichment in indel rates in 3′ UTRs, and alternative 3′ UTR splicing contributes to
disease severity and susceptibility18,23. We suggest that, in addition to modifying disease,
3′ UTR variation may also account for phenotypic variation in physiological traits. Ogn is
an ECM protein and a member of the small leucine-rich repeat protein family19,24. ECM
proteins are increasingly recognized as major determinants of the hypertrophic response
acting, in part, through modulation of the transforming growth factor beta (TGF-β) signaling
pathway15,16. Furthermore, mouse studies have shown that the TGF-β signaling is
important for cardiac hypertrophy secondary to aortic banding25. Therefore, we speculate
that Ogn may influence LVM through modulation of the TGF-β pathway. A role for the
TGF-β signaling pathway in the regulation of LVM is supported by our data that show an
association of LVM in humans with several important genes in this pathway (ASPN, FBN1,
FSTL1, LTBP, TUBA1B and TUBA1C) (Table 1). In conclusion, we propose that variation
of LVM is explained by the interplay of genetic factors6 and hemodynamic components
other than conventional measures of blood pressures or aortic stenosis26. Discovery of
genes, such as Ogn, and pathways that intrinsically regulate LVM may help identify new
approaches for treating human heart disease.
METHODS
Rats and mice
The BXH/HXB RI strain panel has been described in detail elsewhere1,5. We determined
indexed LVM by averaging measurements of LVM corrected for body weight in four to six
male rats within each RI strain5. For microarray studies, we collected hearts from four males
of each RI strain and five from each parental strain; the apex of the left ventricle was
isolated and frozen in liquid nitrogen. Immunoblotting was performed using 8-week-old
male BN and SHR males (Charles River). Ogn−/− mice were made as previously
described19 and backcrossed to C57BL/6 for more than 10 generations. Details of the 27
other rat strains used are given in Supplementary Table 9 online. We studied male mice
between 9 and 17 weeks old in age-matched groups. All animal procedures were performed
under license from the UK Home Office or in accordance with the Animal Protection Law
of the Czech Republic.
Blood pressure measurements
In the rat studies, we implanted indwelling aortic radiotelemetry transducers (Data Sciences
International) at 8 weeks of age and measured arterial pressure in conscious, unrestrained
rats. Radiotelemetry pressure was collected in 5-s bursts every 10 min and recorded over a
period of 8 d, using 6–12 rats within each RI strain. For studies in mice, we measured tail
cuff blood pressures in conscious mice that were preacclimatized to experimental conditions
for 2 weeks. Blood pressure values were averaged within each RI strains and across eight
sequential readings, three times per week (2 weeks before and after pump insertion).
Microarray data
RNA was extracted from heart samples and prepared for microarray analysis as previously
described1. We used the Affymetrix RAE 230 2.0 and the Affymetrix U133A microarrays
for rat and human studies, respectively. Gene expression summary values for Affymetrix
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GeneChip data were computed using the Robust Multichip Average (RMA) algorithm as
described1. Relative changes were determined by RMA values, backtransformed (anti-log2)
to raw intensity scale.
Expression QTL mapping
For each transcript on the microarray, eQTL linkages and false discovery rate (FDR) at a
given genome-wide significance level (PGW) were determined as previously described1. We
determined which eQTLs were regulated in cis or in trans by defining cis eQTLs as those
with a peak of linkage within 10 Mbp of the physical location of the probe set1. To avoid
misclassification of cis and trans eQTLs, probe sets whose physical position mapped to
more than one place in the genome were removed from the dataset8.
Quantitative trait transcript analysis
We assessed association between gene expression levels and phenotypic variation across the
population by correlating transcript abundance with the values of physiological traits2.
Pearson correlation coefficients (r) and Westfall-Young corrected P values based on 10,000
permutations were calculated using Matlab version 6 (Supplementary Table 4).
QTL mapping of LVM
We performed linkage analysis of LVM data in MapManager QTXb20 using the expanded
1,011 marker set1 with another 17 fluorescently labeled microsatellite markers within the
region of interest on rat chromosome 17p14 (Supplementary Table 10 online).
Amplification products of microsatellite markers across the RI strain panel were detected on
a 3730xl DNA Analyzer (Applied Biosystems) and genotype data analyzed using
GeneMapper version 3.7 (Applied Biosystems). To refine the boundaries of the LVM QTL
on rat chromosome 17p14, we carried out fine mapping of LVM using 46 informative SNPs
within the QTL region. SNPs were retrieved from the STAR project consortium (see URLs
below).
RT-PCR of Ogn 3′ UTR
RNA was quantified by a standard curve (RiboGreen, Invitrogen), treated with DNase I
(Invitrogen) and used to make cDNA with AMV reverse transcriptase (Roche). After cDNA
clean up (MicroSpin G-50 columns, Amersham), we carried out PCR was with KOD Hot
Start DNA Polymerase (Novagen). PCR conditions were 95 °C (12 min), then 30 cycles of
95 °C, 30 s; 62 °C, 30 s. PCR products were visualized on a 1.5% agarose gel with ethidium
bromide. Primer pairs are given in Supplementary Methods online.
Quantitative RT-PCR
We used the One-Step TaqMan RT-PCR Master Mix (Applied Biosystems) with
normalization to total RNA as previously described1. Quantification of the Ogn 3′ UTR
variants and assays of mouse left ventricle were performed by two-step quantitative RT-
PCR (iScript cDNA Synthesis, Bio-Rad; SYBR Green I JumpStart Taq Readymix, Sigma)
as per manufacturer's instructions. Primers pairs and PCR conditions are given in
Supplementary Methods.
Immunoblotting and immunohistochemistry
Protein extracts from heart samples were prepared and analyzed by SDS-PAGE and
immunoblotting as previously described27. Antibodies to mouse Ogn were from R&D
Systems (goat, AF2949); those to human Ogn were from Chemicon (rabbit, AB2210), and
secondary antibodies were from R&D or Dako, respectively. After immunoblotting, equal
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loading was confirmed using Ponceau S solution (Sigma). Proteins were quantified with
Quantity One software (Bio-Rad). For immunohistochemistry, adult cardiac myocytes were
isolated, stained and imaged as described in the Supplementary Methods.
Cloning and luciferase assay
The 3′ UTR of Ogn was amplified by PCR from BN and SHR heart cDNA (conditions as
above). PCR products were gel-purified and TA cloned into pTargeT (Promega). Sequence-
verified BN and SHR Ogn 3′ UTRs were subcloned to psiCHECK-2 (Promega). For
luciferase assays, we seeded COS-1 cells in 24-well dishes at a density of 105 cells per well
and transfected them with 100 ng of psiCHECK-2–Ogn 3′ UTR using Lipofectamine 2000.
Cells were collected after 24 h and Renilla and firefly luciferase activity detected using
Dual-Glo Luciferase (Promega).
Neonatal rat cardiac myocytes and cardiac fibroblast cultures
We prepared primary cultures of neonatal rat ventricular cardiac myocytes as previously
described27. After serum starvation (24 h), cells were stimulated with phenylephrine (100
μM) and RNA extracted (RNeasy, Qiagen) at the specified time-points. For cultures of
cardiac fibroblasts, cells were seeded on 60-mm plates during purification of neonatal rat
ventricular myocytes. Fibroblasts were grown to confluence and passaged using standard
approaches and culture conditions as used for cardiac myocytes. Cells were used for
experiments at the third passage.
Human myocardial biopsies for microarray and protein studies
We obtained cardiac needle biopsies specimens from 20 individuals with aortic stenosis
undergoing valve replacement surgery, selected from an extended study group of 45
characterized by echocardiography, and from seven sex-matched subjects without aortic
stenosis at the time of coronary bypass grafting as previously described28 (further details are
given in Supplementary Methods). LVM and aortic valve area index (AVAI) were
calculated using standard echocardiography techniques and normalized to body mass
index17. For differential expression analysis, two groups were selected on the basis of their
LVM: individuals with low LVM (≤93 g/m2, n = 7) and individuals with high LVM (≥142
g/m2, n = 7). The cut-offs were the 25th and 75th percentiles of the LVM distribution,
respectively. The local Ethics Committee of the University Hospital Maastricht approved the
study.
For protein studies, we used a distinct cohort of eight subjects; details are given
Supplementary Table 7. Full-thickness myocardial biopsies were taken at the time of
cardiac surgery with the approval of the Hammersmith Hospital Research Ethics Committee.
We obtained written informed consent from all subjects.
Cardiac MRI study
Individuals with a diagnosis of aortic stenosis who attended the Royal Brompton Hospital,
London cardiac MRI unit between 2002 and 2007 were retrospectively identified from a
local database with the approval of the hospital Research Ethics Committee. This identified
474 people with a diagnosis of aortic stenosis. Of this cohort, 123 had isolated aortic
stenosis in the absence of confounding cardiac valve or myocardial pathology and were used
for the study. The mean age of the subjects was 61.7 years (range 9–89), with 64% males
and 36% females. We acquired MRI cine images, aortic blood flow velocities and
gadolinium-DTPA contrast-enhanced images (1.5 Tesla, Siemens Sonata). LVM, left
ventricular ejection fraction and aortic valve area planimetry, from which LVM and AVAI
were calculated, were determined using standard approaches29.
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Angiotensin II infusion studies
We implanted osmotic pumps (1002, Alzet) subcutaneously under general anesthesia. AII
was infused (1.5 μg/g/day) for 2 weeks, while mice were housed under standard conditions.
After the infusion period, mice were weighed, hearts were collected and the left ventricle
was isolated by removal of the great vessels, atria and the right ventricle; it was then rinsed
and blotted dry. LVMs (expressed as a percentage of body mass) of Ogn−/− mice were
compared to those of littermate or wild-type Ogn+/+ mice and those of littermate Ogn+/−
mice. Data were collected in single-blinded fashion.
Statistical analysis
Data are presented as mean ± s.e.m. and were compared using a Student's t-test (or Mann-
Whitney U-test, as appropriate) or repeated-measures, one-way analysis of variance
followed by Dunnett's post hoc test. We analyzed differential expression in the human
microarray data using Statistical Analysis of Microarrays (SAM) and used 10,000
permutations to estimate the false discovery rate30. Multivariate regression analysis was
carried out to evaluate the effect of indices of disease severity (Vmax, peak velocity of aortic
blood flow and AVAI) on LVM in the cohorts of individuals with aortic stenosis. We built
regression models by adding all significant covariates (P < 0.05), including sex, age and
ejection fraction, and calculated the unique contributions (R2 values) of Vmax and AVAI to
variation of LVM. Calculations were done with SPSS 12.0.
URLs
STAR project consortium, http://www.snp-star.eu/.
Accession codes
ArrayExpress: rat microarray data have been deposited under experiment number E-
MIMR-222. NCBI GEO: human expression data have been deposited with accession code
GSE10161.
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Figure 1.
Quantitative trait transcripts analysis of cis eQTLs with physiological traits in the rat.
Expression profiles of the 1,444 cis eQTLs (PGW = 0.05) were correlated with values of (a)
indexed LVM, (b) DBP and (c) SBP measured in the BXH/HXB RI strain panel. For each
cis eQTL across the rat genome, the absolute Pearson correlation coefficient with the
physiological traits is plotted against the location of the probe set (Mb). Vertical lines,
physical position of the end of each rat chromosome. The number of each chromosome is
given on the upper y axis. The horizontal lines indicate empirical significance levels P =
0.05, P = 0.01 and P = 0.001 of the correlations (see Methods).
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Figure 2.
Candidate cis-regulated genes within the rat QTL for left ventricular mass. (a) Interval
mapping of LVM to chromosome 17p14 in the BXH/HXB RI strain panel. Horizontal
dashed line, genome-wide threshold for significance (P = 0.05) of linkage derived by 10,000
permutations; 2-lod support interval region, by vertical box (dotted lines). Positions of the
genetic markers are also indicated along the x axis. (b) Volcano plot of significance of cis
eQTLs against their relative change in expression. Circles represent 113 transcripts
physically encoded within the 2-lod support interval of the QTL and showing cis linkage at
their nearest markers (nominal P < 0.05, two-tailed Mann-Whitney U-test). For each
transcript, the negative log10 of the P value of linkage is plotted against the relative change
in gene expression at the peak of linkage. Dashed horizontal line, significance threshold (P =
0.00033) after Bonferroni correction for multiple testing owing to the number of transcripts
in the region that were tested for cis linkage. Transcripts representing Hbld2 (one probe set)
and Ogn (two probe sets) are indicated by the arrows. (c) Sequence polymorphisms in Ogn
genomic DNA from 2 kb upstream of the first exon to 3 kb downstream of the stop codon.
For 5′ UTR, exonic and 3′ UTR variants, positions are reported relative to the start codon;
for intronic variants, positions are given relative to the nearest exon. The sequences variation
at position 348 in exon 3 of Ogn is synonymous. Ins, insertion. (d) Regulation of Ogn in a
blood pressure–independent in vitro model of cardiac myocyte hypertrophy: neonatal rat
ventricular myocytes stimulated with phenylephrine for the times shown and assayed by
quantitative RT-PCR for changes in Ogn mRNA expression. Mean relative change (±
s.e.m.) in gene expression as compared to control samples over the time course of the
experiment; *P < 0.05, **P < 0.01.
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Figure 3.
Correlation between hemodynamic indices and indexed LVM in individuals with aortic
stenosis. (a–d) We observed little correlation between LVM and peak velocity across the
aortic valve (Vmax) or indexed aortic valve area (AVAI), indices of aortic stenosis severity
and hemodynamic pressure, in two independent cohorts of subjects with aortic stenosis
characterized by echocardiography (a,b, n = 45) or cardiac MRI (c,d, n = 123), respectively.
The percentage of variance of LVM accounted for by hemodynamic indices after including
all significant covariates (R2) is indicated.
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Figure 4.
Molecular characterization of rat Ogn. (a) PCR products of Ogn 3′ UTR generated from BN
and SHR cDNA, showing the presence of two splice variants. (b) Abundance of the 3′ UTR
isoforms and total coding mRNA in the parental strains. Each data point represents the
relative expression in one BN (circle) or one SHR (triangle) rat of total coding, short and
long isoforms of Ogn. *P < 0.01, **P < 0.001. (c) Abundance of the 3′ UTR isoforms and
total coding mRNA in the RI strains. Each data point represents relative Ogn expression in
one rat from each of the RI strains carrying either the BN (circle) or SHR (triangle) allele;
**P < 10−11. (d) Effects of the BN and SHR 3′ UTR isoforms on protein synthesis as
determined by luciferase assay. Isoforms: BN long, BN-L; BN short, BN-S; SHR long SHR-
L; SHR short, SHR-S. **P < 0.0001. (e) Immunoblot of Ogn protein expression in 20 μg
total protein from three BN and three SHR hearts. Immature pre-Ogn, ~50 kDa, mature Ogn
protein, ~20 kDa. (f) Semiquantitative densitometry of data shown in e. **P < 0.0001. (g)
Immunofluorescence confocal micrographs of isolated adult rat ventricular cardiac
myocytes. Top left, sarcomeric proteins labeled with rhodamine-conjugated phalloidin; top
right, DAPI counterstain of nuclei; bottom left, Ogn protein detected using antibodies to
Ogn and a secondary antibody labeled with Alexa Fluor 488; bottom right, merged image.
Mean ± s.e.m. (d,f); NS, not significant.
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Figure 5.
In vivo regulation of LVM in Ogn knockout mice. (a) Indexed LVM in mice at baseline and
after hypertrophic stimulation by angiotensin II infusion over a 2-week period (n = 14–18
for Ogn+/+, n = 6–10 for Ogn+/− or Ogn−/−). (b) SBP and DBP in mice at baseline and after
angiotensin II infusion (n = 6 for Ogn+/+, n = 3–5 for Ogn+/− or Ogn−/−). All results are
given as mean ± s.e.m. P values were generated by one-way analysis of variance with the
Dunnett's post hoc test for multiple comparisons using the wild-type mice (Ogn+/+) as the
reference group. *P < 0.05; **P = 0.002; NS, not significant.
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